GSA Capital Partners LLP Makes New $505,000 Investment in Myriad Genetics, Inc. (NASDAQ:MYGN)

GSA Capital Partners LLP purchased a new position in Myriad Genetics, Inc. (NASDAQ:MYGN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 18,420 shares of the company’s stock, valued at approximately $505,000.

A number of other large investors have also added to or reduced their stakes in MYGN. ProShare Advisors LLC grew its holdings in Myriad Genetics by 14.2% in the 1st quarter. ProShare Advisors LLC now owns 23,993 shares of the company’s stock worth $512,000 after acquiring an additional 2,990 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Myriad Genetics by 8.9% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 25,107 shares of the company’s stock worth $583,000 after purchasing an additional 2,050 shares during the period. Vanguard Group Inc. lifted its position in shares of Myriad Genetics by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 10,035,708 shares of the company’s stock worth $213,961,000 after purchasing an additional 81,475 shares during the period. Ameritas Investment Partners Inc. lifted its position in shares of Myriad Genetics by 9.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 8,747 shares of the company’s stock worth $186,000 after purchasing an additional 720 shares during the period. Finally, UniSuper Management Pty Ltd purchased a new stake in shares of Myriad Genetics in the 1st quarter worth about $467,000. Institutional investors own 99.02% of the company’s stock.

Insiders Place Their Bets

In other Myriad Genetics news, CEO Paul J. Diaz sold 15,000 shares of Myriad Genetics stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $22.93, for a total value of $343,950.00. Following the completion of the transaction, the chief executive officer now directly owns 962,378 shares of the company’s stock, valued at approximately $22,067,327.54. The trade was a 1.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Colleen F. Reitan sold 46,012 shares of Myriad Genetics stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the completion of the sale, the director now owns 42,533 shares of the company’s stock, valued at $1,188,797.35. This represents a 51.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,012 shares of company stock valued at $1,900,485. Insiders own 2.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on MYGN shares. TD Cowen raised their target price on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Morgan Stanley dropped their target price on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a research report on Monday. Piper Sandler dropped their target price on shares of Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, November 11th. Wells Fargo & Company started coverage on shares of Myriad Genetics in a research report on Tuesday, August 27th. They set an “overweight” rating and a $35.00 price target for the company. Finally, Scotiabank lifted their price target on shares of Myriad Genetics from $29.00 to $34.00 and gave the company a “sector outperform” rating in a research report on Tuesday, August 13th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Myriad Genetics has an average rating of “Hold” and a consensus target price of $27.36.

Myriad Genetics Stock Down 1.4 %

Shares of Myriad Genetics stock opened at $15.00 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The stock has a market capitalization of $1.37 billion, a PE ratio of -11.54 and a beta of 1.93. Myriad Genetics, Inc. has a 52-week low of $14.77 and a 52-week high of $29.30. The company has a 50-day simple moving average of $22.95 and a two-hundred day simple moving average of $24.61.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.